Miglustat

Basic Information

CAS ID: 72599-27-0
Molecular Formula: C10H21NO4
Molecular Weight: 219.3 g/mol
Monoisotopic Mass: 219.1471 g/mol
Class: Small Molecule
Natural Product: No
Other Names: OGT 918 | ZAVESCA | MIGLUSTAT
Analysis: Drug repositioning mechanism analysis

N OH OH OH HO

Compound Structure and Identifier

InChI: InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1 See All
InChI Key: UQRORFVVSGFNRO-UTINFBMNSA-N
Smiles: CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO See All
Molfile: Download

Related Target

Target ID Name Interaction
T0453 Non-lysosomal glucosylceramidase inhibitor

Related Fibrosis Property

Reference Record 1

PubMed ID 25141135 Target ID T0453
Uniprot ID Non-lysosomal glucosylceramidase Name Non-lysosomal glucosylceramidase
Model vitro Fibrosis Disease Cystic fibrosis
Process I attenue inflammation
Process II
Process III
Mechanism

Reference Record 2

PubMed ID 26060255 Target ID
Uniprot ID Name
Model vitro,mice Fibrosis Disease Cystic fibrosis
Process I
Process II
Process III
Mechanism

Trial Record 1

ClinicalTrial ID NCT00945347 Disease Cystic fibrosis
Phase Phase 2 Status Completed
First Received July 24, 2009 Last Verified August 10, 2011
Sponsor Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Trial Record 2

ClinicalTrial ID NCT00537602 Disease Cystic fibrosis
Phase Phase 2 Status Terminated
First Received October 1, 2007 Last Verified February 12, 2010
Sponsor Actelion

Trial Record 3

ClinicalTrial ID NCT02325362 Disease Cystic fibrosis
Phase Phase 2,Phase 3 Status Completed
First Received December 25, 2014 Last Verified March 19, 2018
Sponsor Assistance Publique - Hôpitaux de Paris

Trial Record 4

ClinicalTrial ID NCT00742092 Disease Cystic fibrosis
Phase Phase 2 Status Completed
First Received August 27, 2008 Last Verified March 7, 2014
Sponsor Actelion

Related Link

PubChem: 51634
ChEMBL: CHEMBL1029